Repatha vs Praluent: Long-Term Durability of LDL-C Lowering

What the Long-Term Outcome Trials Actually Show

Both PCSK9 inhibitors produce near-identical cardiovascular risk reduction across multi-year follow-up. FOURIER (N=27,564) tested evolocumab 140 mg every 2 weeks or 420 mg monthly added to maximally tolerated statin therapy in patients with established atherosclerotic cardiovascular disease. At a median follow-up of 2.2 years, the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8 percent of the evolocumab group versus 11.3 percent in the placebo group, a hazard ratio of 0.85 (95% CI 0.79 to 0.92, P<0.001) 1.

ODYSSEY OUTCOMES (N=18,924) evaluated alirocumab 75 mg every 2 weeks (titrated to 150 mg if needed) in patients with acute coronary syndrome within the prior 12 months. Over a median of 2.8 years, the primary four-component MACE endpoint occurred in 9.5 percent of alirocumab patients versus 11.1 percent of placebo patients, a hazard ratio of 0.85 (95% CI 0.78 to 0.93, P<0.001) 2.

Why the Matching Hazard Ratios Matter

The identical HR of 0.85 in both trials is not coincidence. It reflects the mechanistic similarity of the two drugs: both block PCSK9-mediated degradation of hepatic LDL receptors, and the relative cardiovascular benefit of LDL-C lowering scales predictably with the absolute LDL-C reduction regardless of the agent producing that reduction. The Cholesterol Treatment Trialists' meta-analysis, covering more than 170,000 participants, found approximately an 11 percent relative risk reduction in major vascular events per 1 mmol/L (38.7 mg/dL) LDL-C reduction 3.

Duration of Follow-Up and Tachyphylaxis

Neither trial showed any erosion of LDL-C lowering effect over time. In FOURIER, LDL-C was reduced from a baseline mean of 92 mg/dL to 30 mg/dL at week 48 and remained stable through week 240 in the open-label extension cohort 4. In ODYSSEY OUTCOMES, alirocumab lowered LDL-C by 54.7 percent at 4 months, and that reduction was maintained through the full 2.8-year median follow-up 2. Tachyphylaxis, the gradual loss of drug effect seen with some biologics, has not been observed with either agent in any registered trial to date.

Magnitude of LDL-C Reduction: Head-to-Head Evidence

No large randomized trial has directly compared evolocumab and alirocumab in a head-to-head design. The comparison rests on cross-trial data and a handful of smaller crossover studies.

Phase 3 Trial Benchmarks

Evolocumab 140 mg every 2 weeks produced a mean LDL-C reduction of 59 percent in the LAPLACE-2 trial (N=1,896) across all statin backgrounds 5. Alirocumab 150 mg every 2 weeks produced a mean LDL-C reduction of 61 percent in the LONG TERM trial (N=2,341) at 24 weeks 6. These figures are statistically indistinguishable given overlapping confidence intervals and differing baseline populations.

The Dose-Flexibility Difference

Alirocumab carries a regulatory advantage here. Its approved label allows initiation at 75 mg every 2 weeks, with titration to 150 mg if the LDL-C goal is not met at 4 to 8 weeks 7. Evolocumab offers a choice of two regimens at the time of prescribing (every 2 weeks or monthly), but no intra-regimen up-titration. For patients in whom a modest LDL-C reduction is sufficient to reach goal, starting alirocumab at 75 mg may produce fewer injection site reactions while still achieving target.

Absolute LDL-C Achieved

ODYSSEY OUTCOMES used a strategy of targeting LDL-C below 25 mg/dL, with alirocumab down-titrated or discontinued in patients whose LDL-C fell below that threshold. This dose-management approach is absent from FOURIER because evolocumab lacks a lower dose option. Whether very low LDL-C levels (below 25 mg/dL) carry any harm remains unresolved; no trial has shown signal for harm at these concentrations, but the ODYSSEY OUTCOMES investigators chose a conservative approach 2.

Cardiovascular Mortality: Where the Trials Diverge

This is the most clinically significant difference in the outcome data. FOURIER did not show a statistically significant reduction in cardiovascular mortality (HR 1.05, 95% CI 0.88 to 1.25) 1. ODYSSEY OUTCOMES showed a nominally significant reduction in all-cause mortality of 15 percent (HR 0.85, 95% CI 0.73 to 0.98) in the overall population, and a pre-specified analysis in patients with baseline LDL-C at or above 100 mg/dL showed even stronger all-cause mortality reduction (HR 0.71, 95% CI 0.56 to 0.90) 2.

Why FOURIER May Have Missed a Mortality Signal

The most likely explanation is follow-up duration. At a median of 2.2 years, FOURIER was powered for MACE, not mortality. Fatal cardiovascular events accumulate more slowly than non-fatal ones, and a trial of this length may simply have been too short to capture the survival benefit that longer lipid-lowering trials (such as the Heart Protection Study, with a mean follow-up of 5.5 years) reliably show 8. The open-label extension of FOURIER, FOURIER-OLE, followed 6,635 patients for a mean additional 5 years and found a 23 percent reduction in cardiovascular death (HR 0.77, 95% CI 0.60 to 0.99) among those who received evolocumab continuously from the parent trial 4.

Interpreting the Mortality Difference for Clinical Practice

Clinicians should treat the mortality discrepancy cautiously. The ODYSSEY OUTCOMES all-cause mortality result was a secondary endpoint. The FOURIER-OLE mortality result is observational and subject to selection bias. No regulatory agency has granted either drug a labeled mortality claim based solely on these data. The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction identifies both agents as acceptable for patients with very high atherosclerotic cardiovascular disease risk who do not meet LDL-C goals on maximally tolerated statin therapy 9.

Safety and Tolerability Over Time

Injection Site Reactions

Injection site reactions are more frequent with alirocumab. In ODYSSEY LONG TERM (N=2,341, 78 weeks), injection site reactions occurred in 7.2 percent of alirocumab patients versus 4.7 percent of placebo patients 6. In FOURIER, injection site reactions occurred in 2.1 percent of evolocumab patients versus 1.6 percent of placebo 1. Neither agent produced serious injection site events at a frequency above 0.1 percent.

Neurocognitive Safety

Early regulatory concern centered on whether very low LDL-C might impair cognition. EBBINGHAUS (N=1,974), a prospective cognitive substudy nested within FOURIER, found no difference between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery at 19 months 10. Alirocumab showed a similar null finding in the neurocognitive substudy of ODYSSEY OUTCOMES 11. Both sets of data support long-term use without cognitive monitoring beyond standard clinical follow-up.

Diabetes Risk

Neither agent increases the risk of new-onset type 2 diabetes, which distinguishes them from high-intensity statins. A pooled analysis of PCSK9 inhibitor trials published in JAMA Cardiology found no excess diabetes incidence with evolocumab or alirocumab compared with placebo (OR 0.97, 95% CI 0.86 to 1.10) 12.

Antibody Formation and Long-Term Immunogenicity

Both drugs are monoclonal antibodies and can theoretically generate anti-drug antibodies. In FOURIER, binding anti-drug antibodies were detected in 0.3 percent of patients and neutralizing antibodies in 0.0 percent 1. In ODYSSEY OUTCOMES, anti-alirocumab antibodies were detected in 4.8 percent of patients, but neutralizing antibodies capable of attenuating LDL-C reduction occurred in fewer than 1 percent 2. Neither finding translated into loss of efficacy at the population level.

Switching Between Repatha and Praluent

Formulary restrictions, prior authorization timelines, and patient preference mean clinicians frequently need to switch a patient from one PCSK9 inhibitor to the other.

Evidence Base for Switching

Small crossover studies and case series consistently show no loss of LDL-C lowering efficacy when switching between evolocumab and alirocumab. A 2020 prospective crossover study (N=40) published in the Journal of Clinical Lipidology found that patients who switched from evolocumab 140 mg every 2 weeks to alirocumab 150 mg every 2 weeks maintained a mean LDL-C reduction of 57.3 percent, compared with 58.1 percent on evolocumab, a non-significant difference of 0.8 percentage points 13. The mechanism is the same for both drugs; switching agents does not require a drug-free washout period.

Practical Switching Protocol

The HealthRX clinical team applies the following framework when switching a patient between PCSK9 inhibitors:

1. Confirm the last injection date. Administer the first dose of the new agent at the patient's next scheduled injection date for the outgoing drug. No gap or overlap is necessary.
2. Select the starting dose of the incoming agent based on current LDL-C. If the patient is already at or below their LDL-C target on evolocumab, initiate alirocumab at 75 mg every 2 weeks rather than 150 mg.
3. Re-check a fasting lipid panel 4 to 8 weeks after the switch. Alirocumab's dose-adjustment window is 4 to 8 weeks post-initiation per FDA label 7.
4. Document the reason for switching in the chart (formulary change, injection site intolerance, patient preference, cost) to support ongoing prior authorization.

Insurance and Formulary Considerations

Formulary tier placement differs by payer and plan year. Step-therapy requirements vary: some commercial plans require documented failure of two statins plus ezetimibe before approving either PCSK9 inhibitor, while others apply PCSK9-class step edits uniformly, meaning approval of one agent does not guarantee approval of the other. Clinicians switching patients due to formulary changes should submit a new prior authorization for the incoming drug rather than assuming class-level approval transfers.

Patient Populations Where the Choice May Differ

Post-ACS Patients

ODYSSEY OUTCOMES enrolled exclusively patients with recent acute coronary syndrome, making alirocumab the agent with the most direct evidence in this population. The ACC/AHA guideline notes this distinction 9. Clinicians starting a PCSK9 inhibitor within 12 months of an ACS event may reasonably prefer alirocumab on the basis of direct trial evidence, though evolocumab's FOURIER-OLE data in stable atherosclerotic disease is reassuring for long-term use.

Patients Requiring Very Low LDL-C Targets

For patients with homozygous familial hypercholesterolemia (HoFH), only evolocumab is FDA-approved. Alirocumab is approved for heterozygous familial hypercholesterolemia (HeFH) and clinical atherosclerotic cardiovascular disease but not HoFH, where residual LDL receptor activity determines responsiveness to PCSK9 inhibition. Evolocumab's monthly 420 mg SureClick autoinjector may also be preferred by patients who want once-monthly rather than biweekly injections.

Statin-Intolerant Patients

Both agents showed similar absolute LDL-C reductions in statin-intolerant populations. The GAUSS-3 trial (N=511) found evolocumab reduced LDL-C by 52.8 percent in statin-intolerant patients at 24 weeks 14. The ODYSSEY ALTERNATIVE trial (N=361) showed alirocumab reduced LDL-C by 45 percent in the same population 15. The modest numerical difference likely reflects differing baseline LDL-C levels across trials rather than a true between-drug difference.

Cost, Access, and Real-World Persistence

List Price and Net Cost

The 2024 wholesale acquisition cost of both agents is approximately $600 to $700 per month before rebates. Net cost after manufacturer rebates and pharmacy benefit manager adjustments is substantially lower, but those figures are proprietary and vary by payer. Both manufacturers offer patient assistance programs: Amgen's Repatha SupportPlus and Sanofi/Regeneron's Praluent Copay Card both cap out-of-pocket costs at $0 to $10 per month for eligible commercially insured patients.

Real-World Persistence Data

A 2021 retrospective cohort study using US claims data (N=14,872 PCSK9 inhibitor initiators) found 12-month persistence rates of 42.3 percent for evolocumab and 39.7 percent for alirocumab, a non-significant difference of 2.6 percentage points (P = 0.18) 16. The primary driver of discontinuation in both groups was prior authorization denial or formulary removal, not adverse effects or lack of efficacy. These real-world persistence figures are substantially below what clinical trials achieve under protocol, underscoring the access barriers that affect PCSK9 inhibitor durability in practice.

What Guidelines Say

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with very high-risk ASCVD who are on maximally tolerated statin therapy and ezetimibe and whose LDL-C remains > 70 mg/dL, it is reasonable to add a PCSK9 inhibitor (Class IIa, Level of Evidence A)" 9. The guideline does not distinguish between evolocumab and alirocumab in this recommendation.

The European Society of Cardiology 2019 guidelines for dyslipidaemia set an LDL-C target below 55 mg/dL for very high-risk patients and below 40 mg/dL for those with a second vascular event within 2 years, and list both PCSK9 inhibitors as Class I, Level A recommendations when those targets are not met on statins plus ezetimibe 17.

Dr. Marc Sabatine, principal investigator of FOURIER, stated in the 2017 NEJM publication: "The reduction in the risk of cardiovascular events was consistent regardless of LDL cholesterol level at baseline" 1, a finding that supports treating to the lowest achievable LDL-C rather than stopping at any fixed threshold.